Nagai N, Hirata E, Kusuda T, Mukai K, Arihiro K, Ohama K
Department of Obstetrics and Gynecology, Hiroshima University Graduate School of Biological Sciences, Hiroshima, Japan.
Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1187-90. doi: 10.1111/j.1525-1438.2005.00186.x.
Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported. We report a patient with VGPA stage IIA responding to neoadjuvant chemotherapy with docetaxel (60 mg/m2 as an intravenous infusion) and cisplatin (70 mg/m2 as an intra-arterial infusion). At 3 weeks after completing one course of this regimen, the tumor size was reduced from 5.3 x 4.0 cm to 2.0 x 2.0 cm (81.1% reduction), revealed by computed tomography. Accordingly, the patient underwent radical hysterectomy, and there have been no signs of recurrence. Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
宫颈绒毛腺管状乳头状腺癌(VGPA)是一种罕见的肿瘤,其治疗方法鲜有报道。我们报告了一名IIA期VGPA患者,对多西他赛(静脉输注60mg/m²)和顺铂(动脉内输注70mg/m²)新辅助化疗有反应。在完成一个疗程该方案3周后,计算机断层扫描显示肿瘤大小从5.3×4.0cm缩小至2.0×2.0cm(缩小81.1%)。因此,该患者接受了根治性子宫切除术,且无复发迹象。因此,多西他赛和顺铂联合使用对宫颈腺癌新辅助化疗似乎有效。